Candiolo列线图在前列腺癌外照射放疗队列中的外部验证
本研究对2016年发表的Candiolo列线图进行外部验证,纳入561例2003–2012年接受根治性放疗的前列腺癌患者,中位随访50个月。Candiolo列线图对生化进展无生存(bPFS)和临床进展无生存(cPFS)分层均高度显著(P<0.0001),C指数分别为75%和80%,较D'Amico分类约高10%。
要点
- Candiolo列线图对bPFS和cPFS分层均高度显著(P<0.0001)。
- Candiolo列线图C指数bPFS 75%、cPFS 80%,高于D'Amico分类。
- Candiolo列线图识别低/极低危患者占61%,D'Amico仅21%。
核心结论
- Candiolo列线图外部验证总体成功,bPFS和cPFS的C指数较D'Amico对照分类约高10%,支持其在前列腺癌根治性放疗前临床使用。
研究设计与样本
- 回顾性外部验证研究,纳入561例2003–2012年接受根治性放疗的前列腺癌患者。
- 按Candiolo列线图五风险类和D'Amico分类三风险类分组比较,终点为bPFS和cPFS。
- 患者平均前列腺剂量77.7 Gy,76%联合雄激素剥夺治疗,中位随访50个月。
主要发现
- 中位随访50个月,56例(10%)生化复发,30例(5.4%)临床进展。
- Candiolo风险类5年bPFS范围98%至38%,5年cPFS范围98%至50%(极低危至极高危)。
- Candiolo列线图对bPFS和cPFS分层均P<0.0001,D'Amico分类分别为P=0.004和P=0.001。
- Candiolo列线图bPFS和cPFS的C指数分别为75%和80%,D'Amico分类分别为64%和69%。
- Candiolo列线图识别低和极低危患者占61%(D'Amico为21%),高和极高危仅占15%但涵盖48%(27/56)生化复发和63%(19/30)临床进展。
关键数值与推荐
- Candiolo列线图五风险类分布:极低危24%、低危37%、中危24%、高危10%、极高危5%。
- D'Amico分类分布:低危21%、中危40%、高危39%。
临床怎么用
- 可在前列腺癌患者根治性放疗前使用Candiolo列线图进行风险分层,其区分度优于D'Amico分类。
局限性
- 研究为回顾性注册,未报告前瞻性验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: the aim of this study is to perform an external validation for the Candiolo nomogram, a predictive algorithm of biochemical and clinical recurrences in prostate cancer patients treated by radical Radiotherapy, published in 2016 on the journal "Radiation Oncology". METHODS: 561 patients, treated by Radiotherapy with curative intent between 2003 and 2012, were classified according to the five risk-classes of the Candiolo nomogram and the three risk-classes of the D'Amico classification for comparison. Patients were treated with a mean prostatic dose of 77.7 Gy and a combined treatment with Androgen-Deprivation-Therapy in 76% of cases. The end-points of the study were biochemical-progression-free-survival (bPFS) and clinical-Progression-Free-Survival (cPFS). With a median follow-up of 50 months, 56 patients (10%) had a biochemical relapse, and 30 patients (5.4%) a clinical progression. The cases were divided according to D'Amico in low-risk 21%, intermediate 40%, high-risk 39%; according to Candiolo very-low-risk 24%, low 37%, intermediate 24%, high 10%, very-high-risk 5%. Statistically, the Kaplan-Meier survival curves were processed and compared using Log-Rank tests and Harrell-C concordance index. RESULTS: The 5-year bPFS for the Candiolo risk-classes range between 98 and 38%, and the 5-year cPFS between 98 and 50% for very-low and very-high-risk, respectively. The Candiolo nomogram is highly significant for the stratification of both bPFS and cPFS (P < 0.0001), as well as the D'Amico classification (P = 0.004 and P = 0.001, respectively). For the Candiolo nomogram, the C indexes for bPFS and cPFS are 75 and 80%, respectively, while for D'Amico classification they are 64 and 69%, respectively. The Candiolo nomogram can identify a greater number of patients with low and very-low-risk prostate cancer (61% versus 21% according to D'Amico) and it better picks out patients with high and very-high-risk of recurrence, equal to only 15% of the total cases but subject to 48% (27/56) of biochemical relapses and 63% (19/30) of clinical progressions. CONCLUSIONS: the external validation of the Candiolo nomogram was overall successful with C indexes approximately 10% higher than the D'Amico control classification for bPFS and cPFS. Therefore, its clinical use is justified in prostate cancer patients before radical Radiotherapy. Trial registration Retrospectively registered.
引用
- Gabriele D, Guarneri A, Bartoncini S, et al. An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy. Radiat Oncol. 2021. PMID: 33952288. doi:10.1186/s13014-021-01814-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。